- Home
- AAL vs QGEN Comparison
AAL vs QGEN Comparison
Compare AAL & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AAL | QGEN |
|---|---|---|
| Founded | 1930 | 1986 |
| Country | United States | Netherlands |
| Employees | 133700 | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.6B | 10.2B |
| IPO Year | 2004 | 1998 |
Fundamental Metrics
Financial Performance| Metric | AAL | QGEN |
|---|---|---|
| Price | $10.80 | $40.39 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 9 |
| Target Price | $15.58 | ★ $51.30 |
| AVG Volume (30 Days) | ★ 74.0M | 1.8M |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 5.96% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $54,633,000,000.00 | N/A |
| Revenue This Year | $10.06 | $8.23 |
| Revenue Next Year | $5.67 | $5.70 |
| P/E Ratio | $63.53 | ★ $24.01 |
| Revenue Growth | ★ 0.78 | N/A |
| 52 Week Low | $8.50 | $38.13 |
| 52 Week High | $16.50 | $57.82 |
Technical Indicators
Market Signals| Indicator | AAL | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 33.37 | 23.72 |
| Support Level | $10.76 | N/A |
| Resistance Level | $13.77 | $49.11 |
| Average True Range (ATR) | 0.50 | 1.05 |
| MACD | -0.08 | -0.51 |
| Stochastic Oscillator | 17.01 | 1.16 |
Price Performance
Historical ComparisonAbout AAL American Airlines Group Inc.
American Airlines is the world's largest airline by aircraft, capacity, and scheduled revenue passenger miles. Its major US hubs are Dallas/Fort Worth, Charlotte, Chicago, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C. It generates over 30% of US airline revenue connecting Latin America with destinations in the United States. After completing a major fleet renewal, the company has the youngest average fleet of US legacy carriers.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).